Ripretinib is an inhibitor of KIT and PDGFRα (IC50s = 3 and 3.6 nM, respectively).1 It is selective for KIT and PDGFRα over a panel of 300 kinases (IC50s = >100 nM) but does inhibit DDR2, VEGFR2, PDGFRβ, and Tie2 (IC50s = <10 nM for all). It also inhibits mutant isoforms of KIT and PDGFRα, including KITV654A, KITT670I, KITD816H, KITD816V, and PDGFRαD842V (IC50s = 11, 9.2, 18, 25, and 36 nM, respectively). Ripretinib induces apoptosis in ROSA wild-type, and KITD816V- or KITK509I-expressing mast cells in a concentration-dependent manner.2 It reduces tumor growth and increases survival in an imatinib-resistant patient-derived xenograft (PDX) mouse model of gastrointestinal stromal tumors (GISTs) when administered at doses of 50 and 100 mg/kg.1 Formulations containing ripretinib have been used in the treatment of GISTs.
1.Smith, B.D., Kaufman, M.D., Lu, W.-P., et al.Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variantsCancer Cell35(5)738-751(2019) 2.Schneeweiss, M., Peter, B., Bibi, S., et al.The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosisHaematologica103(5)799-809(2018)